--- title: "DoctorDerm 推出品牌重塑，並擴展平台，新增處方皮膚和睫毛治療" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/286923716.md" description: "DoctorDerm 宣佈進行全面的品牌重塑，並擴展其遠程皮膚科平台，推出新的處方治療方案。此次品牌重塑強調簡單和個性化護理，摒棄一刀切的解決方案。新產品包括用於改善皮膚質量的銅肽皮膚複合物和用於增強睫毛外觀的睫毛生長精華。這兩種治療方案在經過持證提供者的評估後可在全國範圍內提供，體現了 DoctorDerm 對於可及性和臨牀指導護膚的承諾" datetime: "2026-05-19T13:40:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286923716.md) - [en](https://longbridge.com/en/news/286923716.md) - [zh-HK](https://longbridge.com/zh-HK/news/286923716.md) --- # DoctorDerm 推出品牌重塑，並擴展平台，新增處方皮膚和睫毛治療 SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- DoctorDerm today announced a comprehensive rebrand alongside the expansion of its personalized telehealth dermatology platform, introducing new prescription treatments designed to further its mission of making clinically guided skincare more accessible. The rebrand reflects a sharpened focus on simplicity, personalization, and provider-led care, making prescription dermatology a more seamless, accessible online experience. At the core of DoctorDerm is a model built around licensed providers who create customized treatment plans tailored to individual needs. By combining medical expertise with a streamlined online platform, DoctorDerm continues to move away from one-size-fits-all skincare toward more precise, personalized care. As part of this next phase, DoctorDerm is introducing two new prescription offerings: The Copper Peptide Skin Complex is a compounded topical formulation featuring GHK-Cu Acetate, a bioactive peptide associated with collagen support and skin appearance and overall quality. The treatment is designed to support skin firmness, texture, and overall quality while reinforcing the skin barrier. The Lash Growth Serum combines Bimatoprost 0.05% and Latanoprost 0.003%, two clinically recognized prostaglandin analogs used to support longer, fuller, and darker lashes over time. Both treatments are available nationwide following evaluation by a licensed provider and reflect DoctorDerm's continued investment in expanding its prescription offerings across skin and hair-related concerns. The rebrand and product expansion mark a broader evolution for DoctorDerm as it continues to scale a more accessible, clinically grounded approach to skincare that is centered on personalization, consistency, and long-term results. **About DoctorDerm** DoctorDerm is a telehealth skincare platform delivering personalized, prescription-grade dermatologic care. Through licensed providers and customized formulations, DoctorDerm helps patients address a range of skin and hair concerns with clinically guided treatments designed for long-term goals—without the barriers of traditional in-office visits. Disclaimer: "Treatments may include compounded prescription medications that are not FDA-approved. These medications are prescribed following evaluation by a licensed provider. Individual results may vary." **Media Contact:** Jamie Neider 801.520.5785 414880@email4pr.com View original content to download multimedia:https://www.prnewswire.com/news-releases/doctorderm-unveils-rebrand-and-expands-platform-with-new-prescription-skin-and-lash-treatments-302776224.html SOURCE DoctorDerm ### 相關股票 - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md) - [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [IXJ.US](https://longbridge.com/zh-HK/quote/IXJ.US.md) ## 相關資訊與研究 - [巨生醫獲 SelectUSA 醫療科技組金牌 啟動美國 A 輪募資目標 1000 萬美元](https://longbridge.com/zh-HK/news/286905054.md) - [鉅亨速報 - Factset 最新調查：碩騰 ZTS-US 的目標價調降至 117 元，幅度約 10%](https://longbridge.com/zh-HK/news/286769910.md) - [ADHD 用藥「利他能」缺貨...網友疑考季因素 食藥署：藥廠早通知控貨中](https://longbridge.com/zh-HK/news/286754700.md) - [分析師重申對 Dermata Therapeutics 的買入評級，並將 12 個月的目標價維持在 4 美元不變](https://longbridge.com/zh-HK/news/286958909.md) - [Ocular Therapeutix（OCUL）在收入持平的情況下，虧損增加是否還能支持其研發雄心？](https://longbridge.com/zh-HK/news/286962966.md)